News
Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results